Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.72)
# 314
Out of 5,182 analysts
34
Total ratings
67.86%
Success rate
36.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Overweight | $144 → $167 | $146.95 | +13.64% | 3 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $44 → $48 | $30.00 | +60.00% | 2 | Apr 14, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $11 → $16 | $22.66 | -29.39% | 4 | Mar 31, 2026 | |
| NUVL Nuvalent | Initiates: Overweight | $116 | $104.75 | +10.74% | 1 | Mar 30, 2026 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $8 → $27 | - | - | 1 | Mar 24, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $15 → $17 | $14.91 | +14.02% | 4 | Mar 17, 2026 | |
| GMAB Genmab | Initiates: Overweight | $40 | $26.47 | +51.11% | 1 | Mar 2, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $50.97 | +3.98% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $24.95 | -7.82% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $45.03 | -22.27% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $25 → $33 | $28.70 | +14.98% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $28.80 | +108.33% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $27 | $13.26 | +103.62% | 3 | Aug 7, 2025 |
Revolution Medicines
Apr 14, 2026
Maintains: Overweight
Price Target: $144 → $167
Current: $146.95
Upside: +13.64%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Overweight
Price Target: $44 → $48
Current: $30.00
Upside: +60.00%
Bicara Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $22.66
Upside: -29.39%
Nuvalent
Mar 30, 2026
Initiates: Overweight
Price Target: $116
Current: $104.75
Upside: +10.74%
Sutro Biopharma
Mar 24, 2026
Upgrades: Overweight
Price Target: $8 → $27
Current: -
Upside: -
Relay Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $15 → $17
Current: $14.91
Upside: +14.02%
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $26.47
Upside: +51.11%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $50.97
Upside: +3.98%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $24.95
Upside: -7.82%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $45.03
Upside: -22.27%
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $28.70
Upside: +14.98%
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $28.80
Upside: +108.33%
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $13.26
Upside: +103.62%